Rep. Bruce Westerman Purchases Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

18 Apr 2025, 17:08 by Renee Jackson · The Cerbat Gem

Representative Bruce Westerman (R-Arkansas) recently bought shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Thermo Fisher Scientific stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $10.68 during trading hours on Friday, hitting $426.11. 3,037,150 shares of the company were exchanged, compared to its average volume of 1,716,463. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The company has a market capitalization of $160.85 billion, a PE ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a fifty day simple moving average of $500.05 and a 200-day simple moving average of $534.93.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Nordea Investment Management AB lifted its position in shares of Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company’s stock worth $28,868,000 after buying an additional 10,606 shares in the last quarter. S.E.E.D. Planning Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.2% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock worth $5,528,000 after purchasing an additional 618 shares during the period. Czech National Bank raised its holdings in Thermo Fisher Scientific by 6.6% during the 4th quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock valued at $43,145,000 after buying an additional 5,118 shares during the period. Douglas Lane & Associates LLC increased its position in Thermo Fisher Scientific by 1.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock valued at $94,948,000 after acquiring an additional 3,460 shares during the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 3rd quarter. M&T Bank Corp now owns 113,347 shares of the medical research company’s stock worth $70,113,000 after acquiring an additional 4,584 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research report on Friday, January 10th. Scotiabank lifted their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 31st. Finally, UBS Group raised their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $642.67.

Get Our Latest Stock Analysis on TMO

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,900 shares of company stock worth $13,106,062. Insiders own 0.34% of the company’s stock.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Thermo Fisher Scientific Company Profile

(Get Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.